ClinicalTrials.gg
Status unknownNCT03396393Updated Jan 23, 2018

Exploratory Study of DHA in Systemic Lupus Erythematosus Patients

A Phase 2 interventional study of Dihydroartemisinin tablet and Placebo tablet in Systemic Lupus Erythematosus, sponsored by Kunming Pharmaceuticals, Inc.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Kunming Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of the study is to assess the efficacy of DHA in patients with SLE.

Read the detailed description

This is a Phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the Safety, Pharmacokinetics and Efficacy of four oral treatment regimens of DHA versus placebo while taking standard of care (SOC) treatment with corticosteroids in adult subjects with Systemic Lupus Erythematosus (SLE).

02

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Dihydroartemisinin;Systemic Lupus Erythematosus
03

In context

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

This study's planned enrollment of 120 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.

Browse Lupus Erythematosus, Systemic studies →

Lead sponsor

Kunming Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Fulfill at least 4 diagnostic criteria for SLE defined by American College of Rheumatology;
  2. Positive antinuclear antibodies (ANA);
  3. Activity Index (SLEDAI) score must be 6-11 points, inclusive;
  4. Stable dose of prednisone (\<30mg/d) for at least one month ;
  5. Active mild to moderate SLE activity as demonstrated by British Isles Lupus Assessment Group Index (BILAG);
  6. Males or females between 18 and 65 years old;
  7. Weight of 45 kg or greater.

Key Exclusion Criteria:

  1. Active Severe Lupus as defined by BILAG Index Level A or two or more of Level B in any body system/organ;
  2. Subjects with concurrent relevant medical conditions like defined chronic infections or high risk of new significant infections;
  3. Presence of active central nervous system (CNS) disease requiring treatment;
  4. Subjects with active, severe SLE disease activity which involves the renal system;
  5. Substance abuse or dependence;
  6. History of malignant cancer within the last 5 years;
  7. Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion;
  8. Subjects received any within the 30 days prior to Visit 2;
  9. Subjects received intravenous immunoglobulin (IVIg) or,plasmapheresis,or High dose prednisone or equivalent (> 100 mg/day) within 90 days prior to Visit 2;
  10. Subjects who have had therapy with cyclophosphamide within 180 days prior to Visit 2 .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Dihydroartemisinin 40mg

    Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.

    Drug: Dihydroartemisinin tablet

  • Experimental
    Dihydroartemisinin 80mg

    Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.

    Drug: Dihydroartemisinin tablet

  • Experimental
    Dihydroartemisinin 120mg

    Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.

    Drug: Dihydroartemisinin tablet

  • Placebo comparator
    placebo

    Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.

    Drug: Placebo tablet

Interventions

  • DHA tablet

    Also known as: No other names

  • DrugPlacebo tablet

    Placebo tablet

    Also known as: No other names

06

What researchers measure

Primary outcomes

  1. SRI,Response at Week 24 according to a combined response index

    The combined response index incorporates the Bristish Isles Lupus Assessment Group (BILAG) assessment, the Systemic Lupus Eyrthematosus Disease Activity Index (SLEDAI), a physician's global assessment of disease activity, and treatment failure status.

    Time frame: week 24

Secondary outcomes

  1. Change from baseline in SLEDAI score

    Change from baseline in SLEDAI score at week 4,8,12,16,20,24

    Time frame: week 4,8,12,16,20,24

  2. Change from baseline in PAG score

    Change from baseline in PAG score at week 4,8,12,16,20,24

    Time frame: week 4,8,12,16,20,24

  3. Number of days of daily prednisone dose Less than or equal to 7.5 mg/day

    Number of days of daily prednisone dose Less than or equal to 7.5 mg/day from baseline over 24 weeks

    Time frame: Baseline, Week 24

  4. Percent of subjects with UPRO <0.5g/24h

    Percent of subjects with UPRO \<0.5g/24h from baseline at Week 4,12,24

    Time frame: Week 4,12,24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — This study has not been decided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2018; primary completion for Dec 2021, 45 months later.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's planned 45 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2018
First posted
Jan 11, 2018
StartEst.
Mar 2018
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2022
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03396393
Lead sponsor
Kunming Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 11, 2018
Start date
Mar 2018 (estimated)
Primary completion
Dec 2021 (estimated)
Completion
Dec 2022 (estimated)
Last update
Jan 23, 2018

Study contacts

Xinyan Li, Ph.D
Contact
xinyan.li@holley.cn
+86-13817688857
Wenyu Xu, Ph.D
Contact
wenyu.xu@holley.cn
+86-10-58611349
Fengchun Zhang, Prof.
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artenimol

Start the discussion